These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 31054981)

  • 61. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
    J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Changes in liver stiffness and steatosis among patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
    Kobayashi N; Iijima H; Tada T; Kumada T; Yoshida M; Aoki T; Nishimura T; Nakano C; Takata R; Yoh K; Ishii A; Takashima T; Sakai Y; Aizawa N; Nishikawa H; Ikeda N; Iwata Y; Enomoto H; Hirota S; Fujimoto J; Nishiguchi S
    Eur J Gastroenterol Hepatol; 2018 May; 30(5):546-551. PubMed ID: 29494353
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy.
    Gupta A; Dhiman RK; Kumari S; Rana S; Agarwal R; Duseja A; Chawla Y
    J Hepatol; 2010 Nov; 53(5):849-55. PubMed ID: 20675008
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy.
    Sidhu SS; Goyal O; Parker RA; Kishore H; Sood A
    Liver Int; 2016 Mar; 36(3):378-85. PubMed ID: 26201713
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Course of liver fibrosis in HIV-hepatitis C virus-coinfected patients depending on the response to hepatitis C therapy.
    Cartón JA; Collazos J; de la Fuente B; Asensi V
    AIDS Res Hum Retroviruses; 2013 Feb; 29(2):215-22. PubMed ID: 22734850
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis.
    Abd Alla MDA; El Awady MK; Dawood RM; Elhawary MA; Al-Azhari SS; Galal AGM
    Arch Virol; 2018 Oct; 163(10):2765-2774. PubMed ID: 29971486
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Prevalence of Helicobacter pylori Infection in Patients with Minimal Hepatic Encephalopathy.
    Schulz C; Schütte K; Reisener N; Voss J; Malfertheiner P
    J Gastrointestin Liver Dis; 2016 Jun; 25(2):191-5. PubMed ID: 27308650
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Liver stiffness predicts clinical outcome in human immunodeficiency virus/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Merchante N; Rivero-Juárez A; Téllez F; Merino D; José Ríos-Villegas M; Márquez-Solero M; Omar M; Macías J; Camacho A; Pérez-Pérez M; Gómez-Mateos J; Rivero A; Antonio Pineda J;
    Hepatology; 2012 Jul; 56(1):228-38. PubMed ID: 22278746
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals.
    Ravaioli F; Conti F; Brillanti S; Andreone P; Mazzella G; Buonfiglioli F; Serio I; Verrucchi G; Bacchi Reggiani ML; Colli A; Marasco G; Colecchia A; Festi D
    Dig Liver Dis; 2018 Jun; 50(6):573-579. PubMed ID: 29567413
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Critical flickering frequency test: a diagnostic tool for minimal hepatic encephalopathy.
    Metwally MA; Biomy HA; Omar MZ; Sakr AI
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1030-1034. PubMed ID: 31274595
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Evaluation of the prognostic value of liver stiffness in patients with hepatitis C virus treated with triple or dual antiviral therapy: A prospective pilot study.
    Stasi C; Piluso A; Arena U; Salomoni E; Montalto P; Monti M; Boldrini B; Corti G; Marra F; Laffi G; Milani S; Zignego AL
    World J Gastroenterol; 2015 Mar; 21(10):3013-9. PubMed ID: 25780300
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Regression of liver fibrosis is progressive after sustained virological response to HCV therapy in patients with hepatitis C and HIV coinfection.
    Casado JL; Quereda C; Moreno A; Pérez-Elías MJ; Martí-Belda P; Moreno S
    J Viral Hepat; 2013 Dec; 20(12):829-37. PubMed ID: 24304452
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Validation of the Korean Stroop Test in Diagnosis of Minimal Hepatic Encephalopathy.
    Yoon EL; Jun DW; Jeong JY; Kim TY; Song DS; Ahn SB; Kim HY; Jung YK; Song MJ; Kim SE; Kim HS; Jeong SW; Kim SG; Lee TH; Cho YK; Kim JK; Ryu H
    Sci Rep; 2019 May; 9(1):8027. PubMed ID: 31142824
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection.
    Tapper EB; Parikh ND; Green PK; Berry K; Waljee AK; Moon AM; Ioannou GN
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1197-1206.e7. PubMed ID: 31589975
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Safety and Effectiveness of Direct-Acting Antiviral Agents for Treatment of Patients With Chronic Hepatitis C Virus Infection and Cirrhosis.
    Maan R; van Tilborg M; Deterding K; Ramji A; van der Meer AJ; Wong F; Fung S; Sherman M; Manns MP; Cornberg M; Hansen BE; Wedemeyer H; Janssen HL; de Knegt RJ; Feld JJ
    Clin Gastroenterol Hepatol; 2016 Dec; 14(12):1821-1830.e6. PubMed ID: 27404965
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy.
    Romero-Gómez M; Córdoba J; Jover R; del Olmo JA; Ramírez M; Rey R; de Madaria E; Montoliu C; Nuñez D; Flavia M; Compañy L; Rodrigo JM; Felipo V
    Hepatology; 2007 Apr; 45(4):879-85. PubMed ID: 17393525
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia: results of hepatology clinic HEPA experience.
    Dolmazashvili E; Abutidze A; Chkhartishvili N; Karchava M; Sharvadze L; Tsertsvadze T
    Eur J Gastroenterol Hepatol; 2017 Nov; 29(11):1223-1230. PubMed ID: 28857900
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.
    Nahon P; Bourcier V; Layese R; Audureau E; Cagnot C; Marcellin P; Guyader D; Fontaine H; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Leroy V; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Dharancy S; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Zucman D; Di Martino V; Thibaut V; Salmon D; Ziol M; Sutton A; Pol S; Roudot-Thoraval F;
    Gastroenterology; 2017 Jan; 152(1):142-156.e2. PubMed ID: 27641509
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy.
    Romero-Gómez M; Ramos-Guerrero R; Grande L; de Terán LC; Corpas R; Camacho I; Bautista JD
    J Hepatol; 2004 Jul; 41(1):49-54. PubMed ID: 15246207
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
    Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK
    Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.